Additionally, OW sema T2D had a positive impact on body weight, showing greater reductions in body weight than different comparators such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, daily subcutaneous GLP-1 RAs, other once-weekly subcutaneous GLP-1 RAs, and insulin medications tested in the trials.19,20. The gene discussed is INS; the disease is type 2 diabetes mellitus.